Abstract
Glioblastoma (GBM), a malignant brain tumor, is a world-wide health problem because of its poor prognosis and high rates of recurrence and mortality. Apolipoprotein C1 (APOC1) is the smallest of apolipoproteins, implicated in many diseases. Recent studies have shown that APOC1 promotes tumorigenesis and development of several types of cancer. In this study we investigated the role of APOC1 in GBM tumorigenesis. Using in silico assays we showed that APOC1 was highly expressed in GBM tissues and its expression was closely related to GBM progression. We showed that APOC1 protein expression was markedly increased in four GBM cell lines (U251, U138, A172 and U87) compared to the normal brain glia cell lines (HEB, HA1800). In U251 cells, overexpression of APOC1 promoted cell proliferation, migration, invasion and colony information, which was reversed by APOC1 knockdown. APOC1 knockdown also markedly inhibited the growth of GBM xenografts in the ventricle of nude mice. We further demonstrated that APOC1 reduced ferroptosis by inhibiting KEAP1, promoting nuclear translocation of NRF2 and increasing expression of HO-1 and NQO1 in GBM cells. APOC1 also induced ferroptosis resistance by increasing cystathionine beta-synthase (CBS) expression, which promoted trans-sulfuration and increased GSH synthesis, ultimately leading to an increase in glutathione peroxidase-4 (GPX4). Thus, APOC1 plays a key role in GBM tumorigenesis, conferring resistance to ferroptosis, and may be a promising therapeutic target for GBM.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Change history
16 August 2022
A Correction to this paper has been published: https://doi.org/10.1038/s41401-022-00969-5
13 May 2024
A Correction to this paper has been published: https://doi.org/10.1038/s41401-024-01271-2
References
Chen R, Smith-Cohn M, Cohen A, Colman H. Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics: the journal of the American Society for Experimental. NeuroTherapeutics. 2017;14:284–97.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–20.
Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma–are we there yet? Neuro Oncol. 2013;15:4–27.
Kumar AA, Abraham Koshy A. Regression of recurrent high-grade glioma with temozolomide, dexamethasone, and levetiracetam: case report and review of the literature. World Neurosurg. 2017;108:990.e11–e16.
Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.
McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34:981–98.
Jong MC, van Dijk KW, Dahlmans VE, Van der Boom H, Kobayashi K, Oka K, et al. Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem J. 1999;338:281–7.
Jong MC, Dahlmans VE, van Gorp PJ, van Dijk KW, Breuer ML, Hofker MH, et al. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest. 1996;98:2259–67.
Takano S, Yoshitomi H, Togawa A, Sogawa K, Shida T, Kimura F, et al. Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene. 2008;27:2810–22.
Yi J, Ren L, Wu J, Li W, Zheng X, Du G, et al. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer. Ann Transl Med. 2019;7:380.
Jin Y, Yang Y, Su Y, Ye X, Liu W, Yang Q, et al. Identification a novel clinical biomarker in early diagnosis of human non-small cell lung cancer. Glycoconj J. 2019;36:57–68.
Sun Y, Zhang J, Guo F, Zhao W, Zhan Y, Liu C, et al. Identification of Apolipoprotein C-I peptides as a potential biomarker and its biological roles in breast cancer. Med Sci Monit. 2016;22:1152–60.
Zhang Q, Wang J, Dong R, Yang S, Zheng S. Identification of novel serum biomarkers in child nephroblastoma using proteomics technology. Mol Biol Rep. 2011;38:631–8.
Fan Y, Shi L, Liu Q, Dong R, Zhang Q, Yang S, et al. Discovery and identification of potential biomarkers of papillary thyroid carcinoma. Mol Cancer. 2009;8:79.
Ouyang J, Jiang Y, Deng C, Zhong Z, Lan Q. Doxorubicin Delivered via ApoE-directed reduction-sensitive polymersomes potently inhibit orthotopic human glioblastoma xenografts in nude mice. Int J Nanomed. 2021;16:4105–15.
Evangelou P, Groll M, Oppermann H, Gaunitz F, Eisenlöffel C, Müller W, et al. Assessment of ApoC1, LuzP6, C12orf75 and OCC-1 in cystic glioblastoma using MALDI-TOF mass spectrometry, immunohistochemistry and qRT-PCR. Med Mol Morphol. 2019;52:217–25.
Cao J, Dixon S. Mechanisms of ferroptosis. Cell Mol life Sci: CMLS. 2016;73:2195–209.
Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830–49.
Li J, Cao F, Yin H, Huang Z, Lin Z, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11:88.
Zhang Y, Fu X, Jia J, Wikerholmen T, Xi K, Kong Y, et al. Glioblastoma therapy using codelivery of cisplatin and glutathione peroxidase targeting siRNA from iron oxide nanoparticles. ACS Appl Mater interfaces. 2020;12:43408–21.
Chen T, Chuang J, Ko C, Kao T, Yang P, Yu C, et al. AR ubiquitination induced by the curcumin analog suppresses growth of temozolomide-resistant glioblastoma through disrupting GPX4-Mediated redox homeostasis. Redox Biol. 2020;30:101413.
Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology (Baltimore. Md). 2016;63:173–84.
Fan Z, Wirth A, Chen D, Wruck C, Rauh M, Buchfelder M, et al. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis. 2017;6:e371.
Ye Z, Wang D, Lu Y, He Y, Yu J, Wei W, et al. Vacuolin-1 inhibits endosomal trafficking and metastasis via CapZβ. Oncogene. 2021;40:1775–91.
Tang J, Li J, Qi W, Qiu W, Li P, Li B, et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab. 2011;13:44–56.
Dodson M, Castro-Portuguez R, Zhang D. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 2019;23:101107.
Zhu H, Blake S, Chan K, Pearson R, Kang J. βCystathionine -synthase in physiology and cancer. BioMed Res Int. 2018;2018:3205125.
Wang L, Cai H, Hu Y, Liu F, Huang S, Zhou Y, et al. A pharmacological probe identifies cystathionine β-synthase as a new negative regulator for ferroptosis. Cell Death Dis. 2018;9:1005.
Sun Y, Chen P, Zhai B, Zhang M, Xiang Y, Fang J, et al. The emerging role of ferroptosis in inflammation. Biomed Pharmacother Biomed Pharmacother. 2020;127:110108.
Friedmann Angeli J, Krysko D, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19:405–14.
Yee P, Wei Y, Kim S, Lu T, Chih S, Lawson C, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat Commun. 2020;11:5424.
Dong X, Zeng Y, Liu Y, You L, Yin X, Fu J, et al. Aloe-emodin: a review of its pharmacology, toxicity, and pharmacokinetics. Phytother Res: PTR. 2020;34:270–81.
Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31:107–25.
Sun X, Niu X, Chen R, He W, Chen D, Kang R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology (Baltimore. Md). 2016;64:488–500.
Chaudhary N, Choudhary B, Shah S, Khapare N, Dwivedi N, Gaikwad A, et al. Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer. Int J Cancer. 2021;149:1495–511.
Liang C, Zhang X, Yang M, Dong X. Recent progress in ferroptosis inducers for cancer therapy. Adv Mater (Deerfield Beach, Fla). 2019;31:e1904197.
Chen L, Li X, Liu L, Yu B, Xue Y, Liu Y. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function. Oncol Rep. 2015;33:1465–74.
Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res. 2018;1865:721–33.
Jiang T, Harder B, Rojo de la Vega M, Wong P, Chapman E, Zhang D. p62 links autophagy and Nrf2 signaling. Free Radic Biol Med. 2015;88:199–204.
Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12:34.
Ulasov A, Rosenkranz A, Georgiev G, Sobolev A. Nrf2/Keap1/ARE signaling: Towards specific regulation. Life Sci. 2022;291:120111.
Jaramillo M, Zhang D. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27:2179–91.
Wang L, Liu Y, Du T, Yang H, Lei L, Guo M, et al. ATF3 promotes erastin-induced ferroptosis by suppressing system Xc. Cell Death Differ. 2020;27:662–75.
Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic Biol Med. 2020;152:175–85.
Paul B, Sbodio J, Snyder S. Cysteine metabolism in neuronal redox homeostasis. Trends Pharmacol Sci. 2018;39:513–24.
Conrad M, Sato H. The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-): cystine supplier and beyond. Amino acids. 2012;42:231–46.
Liu N, Lin X, Huang C. Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance. Br J Cancer. 2020;122:279–92.
Liu J, Xia X, Huang P. xCT: A critical molecule that links cancer metabolism to redox signaling. Mol Ther: J Am Soc Gene Ther. 2020;28:2358–66.
Dong H, Qiang Z, Chai D, Peng J, Xia Y, Hu R, et al. Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1. Aging. 2020;12:12943–59.
Chen D, Tavana O, Chu B, Erber L, Chen Y, Baer R, et al. NRF2 is a major target of ARF in p53-independent tumor suppression. Mol Cell. 2017;68:224–32.e4.
Hayashima K, Kimura I, Katoh H. Role of ferritinophagy in cystine deprivation-induced cell death in glioblastoma cells. Biochem Biophys Res Commun. 2021;539:56–63.
Casique L, Kabil O, Banerjee R, Martinez J, De, Lucca M. Characterization of two pathogenic mutations in cystathionine beta-synthase: different intracellular locations for wild-type and mutant proteins. Gene. 2013;531:117–24.
Floros K, Chawla A, Johnson-Berro M, Khatri R, Stamatouli A, Boikos S, et al. MYCNMYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in -amplified neuroblastoma. Cell Stress. 2022;6:21–9.
Erdélyi K, Ditrói T, Johansson H, Czikora Á, Balog N, Silwal-Pandit L, et al. Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation. Proc Natl Acad Sci USA 2021;118:e2100050118.
Acknowledgements
This research was funded by Beijing Natural Science Foundation (7212157), CAMS Innovation Fund for Medical Sciences (2021-I2M-1-029), National Natural Science Foundation of China (81703536, 81803584, 81703565), Technology Major Projects for “Major New Drugs Innovation and Development” (2018ZX09711001-005-025, 2018ZX09711001-012), Peking Union Medical College Graduate Innovation Fund (2019-1007-07).
Author information
Authors and Affiliations
Contributions
JHW, YW and GHD developed the hypothesis, designed the experiments, and revised the manuscript. XJZ and WLC conducted all experiments and wrote the main manuscript. WL, WQF, JYL and LWR collected data. SL, BBG, YHY, YZZ, HY performed the statistical analysis. JY provided the study materials and patients. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
The original online version of this article was revised: In this article fig. 4 has been updated.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zheng, Xj., Chen, Wl., Yi, J. et al. Apolipoprotein C1 promotes glioblastoma tumorigenesis by reducing KEAP1/NRF2 and CBS-regulated ferroptosis. Acta Pharmacol Sin 43, 2977–2992 (2022). https://doi.org/10.1038/s41401-022-00917-3
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41401-022-00917-3
Keywords
This article is cited by
-
Ioning out glioblastoma: ferroptosis mechanisms and therapeutic frontiers
Cell Death Discovery (2025)
-
KIAA1429 Silencing ameliorates osteosarcoma progression through promoting ferroptosis via Nrf2/NQO1 axis
Inflammation Research (2025)
-
Collagen type I alpha 1 induces radio-resistance in hypoxic glioblastoma cells by promoting autophagy
Journal of Neuro-Oncology (2025)
-
Mapping glioma progression: single-cell RNA sequencing illuminates cell–cell interactions and immune response variability
Discover Oncology (2025)
-
APOC1 is a prognostic biomarker associated with M2 macrophages in ovarian cancer
BMC Cancer (2024)